

CURRICULUM VITAE

Name Giulio Cesare **Spagnoli**

Date of birth 20.10.1952, Roma, Italy

Address

Education

1976 M.D. *Università di Roma, "La Sapienza"*
 1980 *Università Cattolica, Roma, (Hygiene and Preventive Medicine)*
 1984 *Università di Pisa, (Immunohematology)*
 1987 *ECFMG Certificate*
 2010 *GCP advanced course Certificate*

Postdoctoral Training

1977 *Intern, Dpt. of Hygiene and Preventive Medicine, Università Cattolica*
 1978-1981 *Intern, Department of Surgical Pathology, Università di Roma*

Research fellowships

1981 *Visiting Fellow, Dpt. of Immunohematology, University of Leiden, Holland*
 1982-1984 *Guest Fellow, Laboratory of Bacteriology and Medical Microbiology, Istituto Superiore di Sanità, Roma*
 1984-1990 *Research Associate, Istituto C.N.R. Tipizzazione Tissutale, L'Aquila, Italy*
 1986-1988 *Research Fellow in Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA*
 1989 *Stagiaire, Unité d'Immunologie Moleculaire, Institut Pasteur, Paris, France*
 1990-1995 *Senior Research Associate, Zentrum für Lehre und Forschung, University of Basel, Switzerland*
 1995-1999 *Forschungsgruppenleiter, Chirurgische Forschung Abteilung, University of Basel, Switzerland*

(2013) Hoffmann-LaRoche, Basel, Switzerland, Dr. Vaios Karanikas: "Prognostic markers in colorectal cancer" (50'000 CHF).

Language skills: Fluent in Italian (mother language), English, French and German

Main Funding: 8 SNF grants as PI, 7 SNF grants as co-applicant, 1 KTI grant as PI, 1 KTI grant as co-applicant for a total of over 5'000'000 CHF.

Reviewer for Swiss National Fond for Scientific Research (SNF), Swiss Cancer League, Cancer League Beider Basel, Swiss Bridge (CH), Deutsche Forschung Gemeinschaft (DFG), Uni Erlangen, Uni Regensburg (D), Association for International Cancer Research (AICR), Cancer Research UK (UK), Dutch Cancer Society (NL), Istituto Superiore di Sanità (I,) Health Research Board (EIRE), Eur. Res. Council, (EU).

Member of the Scientific Committee of the Cancer League Beider Basel

Membership of scientific societies: American Association for Cancer Research (AACR)

Reviewer for over 30 scientific journals, including: Cancer Research, Clinical Cancer Research, European Journal of Immunology, Vaccine, British Journal of Cancer, International Journal of Cancer, European Journal of Cancer, Cancer Immunology Immunotherapy, Tissue Engineering, Biomaterials, Current Opinions in Drug Discovery and Development, Trends in Biotechnology, Journal of Leukocyte Biology, Drug Discovery Today, Oncotarget, Journal for the Immunotherapy of Cancer.

Main translational projects:

- 1) *HLA-DR tissue typing in patients undergoing hemodialysis waiting for kidney transplantation (1981-1984).*
- 2) *Effects of chloroquine treatment on natural killer activity in patients with rheumatoid arthritis (1984-1986).*
- 3) *Identification of antigenic fractions from Candida albicans cell wall (1984-1986).*
- 4) *Culture of tumor infiltrating lymphocytes from surgical specimens: phenotypic, transcriptional and functional profiling (1990-1997).*
- 5) *Characterization of expression and prognostic significance of cancer/testis tumor associated antigens in human malignancies (1995-2002).*
- 6) *Analysis of IFN- α 2 sensitivity and transcriptional response in melanoma cells (1998-2002).*

- 7) *Active antigen specific immunotherapy of advanced melanoma with recombinant vaccinia virus encoding epitopes from tumor associated antigens and co-stimulatory molecules (2000-2011).*
- 8) *Mechanisms of virosome-mediated adjuvance for vaccine formulations (2002-2006).*
- 9) *Identification of target epitopes for BKV and JCV virus specific vaccination (2006-2009).*
- 10) *Immunosuppressive effects of mesenchymal stromal cells on lymphoproliferation in patients with autoimmune diseases (2007-2014)*
- 11) *Analysis of the prognostic significance of colorectal cancer infiltration by immune cells (2009-2015).*
- 12) *Assessment of drug sensitivity in established cell lines and clinical specimens in perfused bioreactors (2011-).*
- 13) *Development of recombinant vaccinia virus based vectors encoding CD80, CD86, CD40 ligand and multiple tumor associated antigen-derived epitopes for cancer immunotherapy (2010-).*

Main professional achievements:

- 1) *Establishment of the tumor immunology lab at the Institute of Surgical Research of the University of Basel, including generation of tumor infiltrating lymphocyte cultures and analysis of their antigenic specificity and functional activities.*
- 2) *Generation and characterization of a series of monoclonal antibodies recognizing human cancer/testis tumor associated antigens (C/T TAA) in paraffin embedded tissue sections. These reagents have been used worldwide for the analysis of the expression of these antigens in different tumor types and to evaluate its prognostic significance.*
- 3) *In collaboration with Dr. Zajac and Prof. Oertli (Basel), design, pre-clinical and clinical evaluation of an antigen specific active immunotherapy platform based on replication incompetent vaccinia virus recombinant for HLA-class I restricted epitopes from human tumor associated antigens and co-stimulatory molecules. Such reagents have successfully been tested in phase I/II clinical trials in patients with advanced melanoma.*
- 4) *In collaboration with Prof. Ivan Martin (Basel), development of innovative 3D culture methods for the “in vitro” analysis of tumor cells-immune system interactions and for the screening of novel anti-cancer compounds.*
- 5) *In collaboration with Prof. Luigi Terracciano and Prof. Giandomenica Iezzi (Basel): analysis of the prognostic significance of tumor infiltration by a variety of immunocompetent cells. These studies have led to the definition of immunocontexture features highly significantly associated with favorable prognosis in colorectal cancer and to the functional characterization of the corresponding molecular background.*

Mentoring activities:

PhD Students:

Heidi Hörig

Christoph Noppen

Reto Schumacher

Chantal Mengus

Anca Reschner

Sourabh Ghosh

Celia Groeper

Nermin Raafat

Manuele Muraro

Clémentine LeMagnen

Emanuele Trella

MD/PhD:

Christian Hirt

Academic Surgeons

Luis Filgueira

Adrian Merlo

Thomas Kocher

Urs Lüscher

Thomas Salm

Paul Martin Sutter

Claude Fischer

Markus Trutmann

Daniel Oertli

Walter Marti

Eugenia Rimmel

Walter Weber

Axel Schütz

Martin Bolli

Michel Adamina

Christian Nebiker

Urs Güller

Urs von Holzen

Rachel Rosenthal

Steve Wyler

Raoul Drosler

Silvio Däster

Guest Scientists:

Tvrtko Hudolin (Zagreb, Croatia)

Chiara Bocelli-Tyndall (Basel, Switzerland)

Laura Bracci (Rome, Italy)

Giuseppe Sconocchia (Rome, Italy)

Marzieh Ebrahimi (Tehran, Iran)

Maumita Bhattacharjee (Dehli, India)

Junyi Han (Shanghai, PRC)

Original reports

1. Jovine R, Ghezzi F, Spagnoli G. A conversational program for hierarchic and non hierarchic cluster analysis. *Med Inform (Lond)* 1980, 5: 141-154.
2. Taccone-Gallucci M, Giardini O, Ausiello CM, Piazza A, Spagnoli GC, Bandino D, Lubrano R, Kashan S, Evangelista B, Monaco P, Tabilio MR, Valeri M, Citti F, Casciani CU. Vitamin E supplementation in hemodialysis patients: effects on lymphocyte lipid peroxidation and immune response. *Clin Nephrol* 1986, 25: 81-86.
3. Ausiello CM, Barbieri P, Spagnoli GC, Ciompi ML, Casciani CU. "In vivo" effects of chloroquine treatment on spontaneous and interferon induced natural killer activities in rheumatoid arthritis patients. *Clin Exp Rheumatol* 1986, 1: 255-259.
4. Ausiello CM, Spagnoli GC, Boccanera M, Casalnuovo I, Malavasi F, Casciani CU, Cassone A. Proliferation of human peripheral blood mononuclear cells induced by *Candida albicans* and its cell wall fractions. *J Med Microbiol* 1986, 22: 95-102.
5. Sayre PH, Chang HC, Hussey RE, Brown NR, Richardson NE, Spagnoli GC, Clayton LK, Reinherz EL. Molecular cloning and expression of T11 cDNA reveal a novel receptor like structure on human T lymphocytes. *Proc Natl Acad Sci USA* 1987, 84: 2941-2945.
6. Spagnoli GC, Ausiello CM, Cassone A, Casciani CU, Bellone G, Malavasi F. Inhibitory effects of anti HLA-A-B-C heavy chain and anti-beta 2 microglobulin monoclonal antibodies on alloantigen and microbial antigen induced immune responses "in vitro". *Scan J Immunol* 1987, 25: 555-565.
7. Ausiello CM, Spagnoli GC, Antonelli G, Malavasi F, Dianzani F, Casciani CU, Cassone A. Generation and characterization of cytotoxic activity against tumor cell lines in human peripheral blood mononuclear cells stimulated "in vitro" by a glycomannan protein preparation of *Candida albicans*. *J Biol Regulators & Homeostatic Agents* 1987, 1: 59-65.
8. Ausiello CM, Spagnoli GC, Antonelli G, Malavasi F, Casciani CU, Dianzani F. Influence of monoclonal antibodies against HLA class I and class II antigens on IFN γ and IFN α induction. *J Interferon Res* 1987, 7: 133-139.
9. Spagnoli GC, Ausiello CM, Palma C, Alessio M, Del Monte L, Casciani CU. Alloantigen and microbial antigen induced cellular immune responses: inhibitory effects of four anti HLA class II monoclonal antibodies. *Diagnostic and Clinical Immunology* 1988, 5: 355-361.

10. Alcover A, Alberini C, Acuto O, Clayton LK, Transy C, Spagnoli GC, Moingeon P, Lopez P, Reinherz EL. Interdependence of CD3 and CD2 activation pathways in human T lymphocytes. *EMBO J* 1988, 7: 1973-1977.
11. Ausiello CM, Maleci A, Spagnoli GC, Antonelli G, Cassone A. Cell mediated cytotoxicity in glioma bearing patients: differential response of peripheral blood mononuclear cells to stimulation with IL-2 and microbial antigen. *J Neuro Oncology* 1988, 6: 329-359.
12. Ausiello CM, Palma C, Spagnoli GC, Piazza A, Casciani CU, Cassone A. Cytotoxic effectors in human peripheral blood mononuclear cells induced by a mannoprotein complex of *Candida albicans*: a comparison with interleukin-2 activated killer cells. *Cell Immunol* 1989, 122: 349-359.
13. Testi R, Alcover A, Spagnoli GC, Reinherz EL, Acuto O. CD3 Ti+ human thymocyte derived clones displaying a differential response to activation via CD3 TI and CD2. *Cell Immunol* 1989, 122: 350-364.
14. Ausiello CM, Spagnoli GC, Palma C, Masetti R, Magistrelli P, Picciocchi A, Casciani CU. Cell mediated immune response in human hepatic echinococcosis. Analysis of antigen induced lymphoproliferation and NK activity. *J Biol Regulators & Homeostatic Agents* 1989, 3: 146-152.
15. Spagnoli GC, Ausiello CM, Sconocchia G, Amici C, Antonelli G, Sciortino G, Cervelli V, Casciani CU. Generation of non MHC restricted cytotoxic immune responses: effects of "in vitro" hyperthermic treatment. *Adv Exp Med Biol* 1990, 267: 501-506.
16. Spagnoli GC, Ausiello CM, Sconocchia G, Antonelli A, Amici C, Casciani CU. Polymorphic effects of exogenous gangliosides on antigen induced lymphoproliferation and generation of MHC unrestricted cell mediated cytotoxicity. *Int J Immunopharmacol* 1990, 12: 713-720.
17. Jin YJ, Kaplan DR, White M, Spagnoli GC, Roberts TM, Reinherz EL. Stimulation via CD3-Ti but not CD2 induces rapid tyrosine phosphorylation of a 68-kDa protein in the human Jurkat T cell line. *J Immunol* 1990, 144: 647-652.
18. Funaro A, Spagnoli GC, Ausiello CM, Alessio M, Roggero S, Delia D, Zaccoli M, Malavasi F. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. *J Immunol* 1990, 145: 2390-2396.
19. Imberti L, Sottini A, Spagnoli GC, Primi D. Expression of the human V β 8 gene product preferentially correlates with class II major histocompatibility complex restriction specificity. *Eur J Immunol* 1990, 20: 2817-2819.

20. Torosantucci A, Palma C, Boccanera M, Ausiello CM, Spagnoli GC, Cassone A. Immunomodulatory effects of mannoproteins from *Candida albicans*: characterization of immunostimulatory constituents for human peripheral blood mononuclear cells. *J Gen Microbiol* 1990, 136: 2155-2163.
21. Spagnoli GC, Ausiello CM, Sconocchia G, Adorno D, Casciani CU. Gangliosides potentiate cyclosporin A induced suppression of allospecific immune responses. *Transpl Proc* 1991, 23: 342-346.
22. Ausiello CM, Palma C, Maleci A, Spagnoli GC, Amici C, Antonelli G, Casciani CU, Cassone A. Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. *Eur J Cancer* 1991, 27: 646-650.
23. Spagnoli GC, Ausiello CM, Palma C, Bellone G, Ippoliti G, Letarte M, Malavasi F. Functional effects of a monoclonal antibody directed against a distinct epitope on 4F2 molecular complex in human peripheral blood mononuclear cell activation. *Cell Immunol* 1991, 136: 208-218.
24. Ausiello CM, Spagnoli GC, Sconocchia G, Pisani F, Adorno D, Casciani CU. Low responsiveness to *Candida* antigens in kidney transplant recipients. *Microbiologica* 1991, 14: 325-332.
25. Ausiello CM, Antonelli G, Spagnoli GC, Gentile M, Dianzani F. A macrophage derived blastogenic factor - MBF - induces cytokines and cytotoxic effectors in human peripheral blood mononuclear cells. *J Biol Regul Homeostatic Agents* 1992, 6: 8-14.
26. Alcover A, Herve F, Boursier JF, Spagnoli G, Olive D, Mariuzza RA, Acuto O. A soluble form of the human CD8 alpha chain expressed in the Baculovirus system: biochemical characterization and binding to MHC class I. *Mol Immunol* 1993, 30: 55-67.
27. Merlo A, Filgueira L, Zuber M, Harder F, Gratzl O, Juretic A, De Libero G, Heberer M, Spagnoli GC. T cell receptor V-gene usage in neoplasms of the central nervous system : a comparative analysis in cultured tumor infiltrating and peripheral blood T cells. *J Neurosurg* 1993, 78: 630-637.
28. Spagnoli GC, Juretic A, Schultz-Thater E, Dellabona P, Filgueira L, Hörig H, Zuber M, Garotta G, Heberer M. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine activated killer cell activity. *Cell Immunol* 1993, 146: 391-405.

29. Ausiello CM, Adorno D, Grana G, Urbani F, Spagnoli GC, Scoïocchia G, Cococetta N, Casciani CU. Inhibitory effects of gangliosides and cyclosporin-A on lymphocyte activation : analysis of cytokine gene transcripts. *Transpl Proc* 1993, 25: 2315-2316.
30. Filgueira L, Zuber M, Merlo A, Caetano V, Schultz E, Harder F, Spagnoli GC, Heberer M. Cytokine gene transcription in renal cell carcinomas. *Br J Surg*, 1993, 80: 1322-1325.
31. Filgueira L, Zuber M, Juretic A, Lüscher U, Caetano V, Harder F, Garotta G, Heberer M, Spagnoli GC. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes .*Cell Immunol* 1993, 150: 205-218.
32. Filgueira L, Zuber M, Merlo A, Harder F, Heberer M, Spagnoli GC. Effects of different culture protocols on the expression of discrete T cell receptor Variable regions in human tumor infiltrating lymphocytes. *Eur J Cancer*, 1993, 29A: 1754- 1760.
33. Juretic A, Spagnoli GC, Hörig H, Babst R, Von Bremen K, Harder F, Heberer M. Glutamine requirements in the generation of lymphokine activated killer cells. *Clin Nutr* 1994, 13:42-49.
34. Hörig H, Spagnoli GC, Filgueira L, Babst R, Gallati H, Harder F, Juretic A, Heberer M. Exogenous glutamine requirement is confined to late events of T cell activation. *J Cell Biochem*, 1993, 53: 343-351.
35. Merlo A, Juretic A, Zuber M, Filgueira L, Lüscher U, Caetano V, Ulrich J, Gratzl O, Heberer M, Spagnoli GC. Cytokine gene expression in primary brain tumors, metastases and meningiomas suggests specific transcription patterns. *Eur J Cancer*, 1993, 29A: 2118-2125.
36. Ausiello CM, Urbani F, Gessani S, Spagnoli GC, Gomez MJ, Cassone A. Cytokine gene expression in human peripheral blood mononuclear cells stimulated by man-
 37. noprotein constituents from *Candida albicans*. *Infect Immun*, 1993, 61: 4105-4111.
38. Labeta MO, Durieux JJ, Spagnoli G, Fernandez N, Wijdenes J, Herrmann R..
 CD14 and tolerance to lipopolysaccharide : biochemical and functional analysis. *Immunology*, 1993,80:415-423
39. Funaro A, Spagnoli GC, Momo M, Knapp W, Malavasi F. Stimulation of T cells via CD44 requires LFA-1 interactions and IL-2 production. *Hum Immunol*, 1994, 40: 267- 278.

40. . Lüscher U, Filgueira L, Juretic A, Zuber M, Lüscher NJ, Heberer M, Spagnoli GC. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor infiltrating lymphocytes. *Int J Cancer*, 1994, 57: 612-619.
41. . Döhning C, Angman L, Spagnoli G, Lanzavecchia A. T-helper and accessory cell independent cytotoxic responses to human tumor cells transfected with a B7-retroviral vector. *Int J Cancer*, 1994, 57: 754-759.
42. Juretic A, Spagnoli GC, Von Bremen K, Hörig H, Filgueira L, Lüscher U, Babst R, Harder F, Heberer M. Generation of lymphokine activated killer activity in rodents but not in humans is nitric oxide dependent. *Cell Immunol*, 1994, 157: 462-477.
43. Schultz-Thater E, Juretic A, Dellabona P, Luescher U, Siegrist W, Harder F, Heberer M, Spagnoli GC. *MAGE-1 gene product is a cytoplasmic protein* . *Int J Cancer*, 1994, 59: 435-439.
44. Spagnoli GC, Juretic A, Rosso R, Van Bree J, Harder F, Heberer M. Expression of HLA-DR in granulocytes of polytraumatized patients treated with recombinant human GM-CSF. *Hum Immunol*, 1995, 43: 45-50.
45. . Juretic A, Spagnoli GC, Hörig H, Shipman R, Kocher T, Harder F, Heberer M. Tyrosine kinase dependent and independent events induced by IL-2 stimulation : IL-2 mediated NO production required for the induction of LAK cell activity in rat splenocytes is tyrosine kinase independent. *Immunology*, 1995, 85: 325-330.
46. Davico Bonino L, De Monte L, Spagnoli GC, Vola, R, Mariani M, Barone D, Moro AM, Riva P, Nicotra MR, Natali PG, Malavasi F. Bispecific monoclonal antibody anti- CD3 x Tenascin : an immunotherapeutic agent for human glioma. *Int J Cancer*, 1995, 61: 509-615.
47. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC. Identification and intracellular location of *MAGE-3 gene product*. *Cancer Res*, 1995, 55: 2236-2239.
48. Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A, Zuber M, Lüscher U, Harder F, Heberer M. Peptide specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing *MART-1/Melan-A, gp100 and Tyrosinase genes* : a study in an unselected group of HLA-A2.1 positive patients. *Int J Cancer*, 1995, 64: 309-315.

49. Salm T, Sutter PM, Marx A, Gürke L, Harder F, Spagnoli G, Heberer M. *Effects of Verapamil on skeletal muscle function following ischemia and reperfusion. Eur Surg Res, 1996, 28: 75-79.*
50. Juretic A, Spagnoli GC, Hörig H, Gross T, Gallati H, Samija M, Eljuga D, Turic M, Harder F, Heberer M. *Nitric oxide independent inhibitory effects of L-arginine analog N-monomethyl-L-arginine on the generation of interleukin-2 activated cytotoxic activity in humans. Clin Nutr, 1996, 15: 16-20.*
51. Noppen C, Spagnoli GC, Schaefer C. *Isolation of multiple mRNAs from a few eukaryotic cells ; a fast method to obtain template for reverse transcription-PCR (RT-PCR). Biotechniques, 1996, 21: 394-396.*
52. Carrel S, Schreyer M, Spagnoli G, Cerottini J-C, Rimoldi D. *Monoclonal antibodies against recombinant MAGE-1 protein identify a crossreacting 72 kDa antigen which is coexpressed with MAGE-1 protein in melanoma cells. Int J Cancer, 1996, 67: 417-422.*
53. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R. *A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun, 1996, 14: 295-304.*
54. Gudat F, Zuber M, Dürmüller U, Kocher T, Schaefer C, Noppen C, Spagnoli G. *The tumour associated antigen MAGE-1 is detectable in formaline-fixed paraffin sections of malignant melanoma. Virchows Arch, 1996, 429: 77-81.*
55. Juretic A, Jürgens-Göbel J, Schaefer C, Noppen C, Willimann TE, Kocher T, Zuber M, Harder F, Heberer M, Spagnoli GC. *Cytotoxic T lymphocyte responses against mutated p21 ras peptides : an analysis of specific T cell receptor gene usage. Int J Cancer, 1996, 68: 471-478 .*
56. Heberer M, Babst R, Juretic A, Gross T, Hörig H, Harder F, Spagnoli GC. *Role of glutamine in the immune response in critical illness. Nutrition, 1996, 12: 71-72.*
57. Sutter PM, Spagnoli GC, Marx A, Gürke L, Fricker G, Troeger H, Harder F, Heberer M. *Increased surface expression of CD18 and CD11b in leucocytes following tourniquet ischemia in elective hand surgery. World J Surg, 1997, 21: 179-185.*
58. Zajac P, Oertli D, Spagnoli GC, Noppen C, Schaefer C, Heberer M, Marti W. *Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after „in*

- vitro*“ stimulation with a replication incompetent Vaccinia virus encoding MART-1/Melan-A 27-35 epitope. *Int J Cancer*, 1997, 71: 491-496.
59. Fischer C, Gudat F, Stulz P, Noppen C, Schaefer C, Zajac P, Trutmann M, Kocher T, Zuber M, Harder F, Heberer M, Spagnoli GC. High expression of MAGE-3 protein in squamous cell lung carcinoma. *Int J Cancer*, 1997, 71: 1119-1121.
 60. Rosso R, Schäfer D, Fricker R, Brennwald J, Jundt G, Spagnoli G, Harder F, Heberer M. Functional and morphological outcome of knee joint transplantation in dogs depends on control of rejection. *Transplantation*, 1997, 63: 1723-1733.
 61. Marti WR, Zajac P, Spagnoli G, Harder F, Oertli D. Non-replicating recombinant Vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive CD4+ T lymphocytes in vitro. *Cell Immunol*, 1997, 179: 146-152.
 62. Zuber M, Spagnoli GC, Kocher T, Lüscher U, Schaefer C, Noppen C, Gudat F, Harder F, Heberer M. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. *Eur Surg Res*, 1997, 29: 403-410.
 63. Hofbauer GFL, Schaefer C, Noppen C, Böni R, Kamarashev J, Nestle FO, Spagnoli GC, Dummer R. MAGE-3 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma : frequency and distribution. *Am J Pathol*, 1997, 151: 1549-1553.
 64. Guidi, F, Spagnoli GC, Neri G, Paganelli G, Siccardi AG, Guttinger M. Three step tumor targeting via biotin-avidin interaction as a versatile system to elicit T-cell mediated, non MHC restricted, cytotoxic activity against neoplastic cells. *Int J Cancer*, 1998, 76: 443-447.
 65. Noppen C, Schaefer C, Zajac P, Schütz A, Kocher T, Kloth J, Heberer M, Colonna M, De Libero G, Spagnoli GC. C-type lectin-like receptors in peptide specific HLA-class I restricted CTL : differential expression and modulation of effector functions in clones sharing identical TCR structure and epitope specificity. *Eur J Immunol*, 1998, 28: 1134-1142.
 66. Bongiorno L, Marzano M, Marini M, Roda G, Urbani A, Babst R, Spagnoli GC. Age increases leucine enkephalin hydrolysis in human plasma. *Gerontology*, 1999, 45: 10-16.
 67. Trutmann M, Terracciano L, Noppen C, Kloth J, Kaspar M, Peterli R, Tondelli P, Schaefer C, Zajac P, Heberer M, Spagnoli GC. GM-CSF gene expression and protein

- production in human colorectal cancer cell lines and clinical tumor specimens. *Int J Cancer*, 1998, 77: 378-385.
68. Babst R, Bongiorno L, Marini M, Marzano M, Spagnoli G, Roda GL, Urbani A. Age-induced increase of leucine enkephalin enzyme degradation in human plasma. *Peptides*, 1998, 19: 1155-1163.
 69. Zajac P, Schütz A, Oertli D, Noppen C, Schaefer C, Heberer M, Spagnoli GC, Marti WR. Enhanced generation of tumoricidal cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor associated antigens and B7 costimulatory molecules. *Cancer Res*, 1998, 58: 4567-4571.
 70. Marini M, Spagnoli GC, Babst R, Urbani A, Bongiorno L, Roda GL. Trauma decreases leucine enkephalin hydrolysis in human plasma. *J Pharmacol Exp Ther*, 1999, 288: 766-773.
 71. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP. Melanoma cells present a MAGE-3 epitope to CD4⁺ cytotoxic T cells in association with HLA-DR11. *J Exp Med*, 1999, 189: 871-876.
 72. Kariyama K, Higashi T, Kobayashi Y, Nouse K, Nakatsukasa H, Yamano T, Ishizaki M, Kaneyoshi T, Toshikuni N, Ohnishi T, Fujiwara K, Nakayama E, Terracciano L, Spagnoli GC, Tsuji T. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. *Brit J Cancer*, 1999, 8: 1080-1087.
 73. Jantscheff P, Herrmann R, Spagnoli G, Reuter J, Mehtali M, Courtney M, Rochlitz C. Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors : mechanism(s) of elimination of the transgene-carrying cells. *Cancer Immunol Immunother*, 1999, 48: 321-330.
 74. Mackensen A, Wittnebel S, Veelken H, Noppen C, Spagnoli GC, Lindemann A. Induction and large scale expansion of tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells. *Eur Cytokine Netw*, 1999, 10: 329-336.
 75. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, Andre M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T. Genes encoding tumor-specific antigens are expressed in human myeloma cells. *Blood*, 1999, 94: 1156-1164.

76. Lee KD, Chang HK, Jo YK, Kim BS, Lee BH, Lee YW, Lee HK, Hur MH, Spagnoli GC, Yu TH. Expression of MAGE-3 gene product in squamous cell carcinomas of the head and neck. *Anticancer Res*, 1999, 19: 5037-5042.
77. Mackensen A, Herbst B, Cerundolo V, Köhler G, Noppen C, Herr W, Wölfel T, Spagnoli GC, Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated „ in vitro“ from CD34+ hematopoietic progenitor cells. *Int J Cancer*, 2000, 86: 385-392.
78. Spagnoli GC, Kloth J, Terracciano L, Trutmann M, Chklovskaja E, Rimmel E, Noppen C, Zajac P, Kocher T, Heberer M. FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. *Int J Cancer*, 2000, 86: 238-243.
79. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ. Expression of MAGE-antigens in normal tissues and cancer. *Int J Cancer*, 2000, 85: 460-465.
80. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini J-C. Anti MAGE-3 antibody 57B and anti MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. *Int J Cancer*, 2000, 86: 749-751.
81. Landry C, Brasseur F, Spagnoli GC, Boon T, Coulie P, Godelaine D. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. *Int J Cancer*, 2000, 86: 835-841.
82. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Liénard D, Cerundolo V, Cerottini J-C, Romero P. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. *J. Immunol*, 2000, 164: 1125-1131.
83. Chambost H, Van Baren N, Brasseur F, Godelaine D, Theate I, Spagnoli GC, Xerri L, Plumas J, Michel G, Coulie P, Olive D. Expression of gene MAGE-A4 in Reed Sternberg cells. *Blood*, 2000, 95: 3530-3533.
84. Noppen C, Lévy F, Burri L, Zajac P, Rimmel E, Schaefer C, Lüscher U, Heberer M, Spagnoli GC. Naturally processed and concealed HLA-A2.1 restricted epitopes from tumor associated antigen tyrosinase-related protein-2. *Int J Cancer*, 2000, 87: 241-246.
85. Schultz-Thater E, Noppen C, Gudat F, Dürmüller U, Zajac P, Kocher T, Heberer M, Spagnoli GC. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable

- by specific monoclonal antibodies in cell lines and clinical specimens. *Brit J Cancer*, 2000, 83: 204-208.
86. Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma : frequency of expression and correlation with prognostic parameters. *Mod Pathol*, 2000, 13 459-465.
 87. Kocher T, Schraml P, Spagnoli GC, Harder F, Heberer M. Identification of genes differentially expressed in melanoma sublines derived from single surgical specimen characterized by different sensitivity to cytotoxic T-lymphocyte activity. *Schweiz Med Wochenschr*, 2000, 130: 617-624.
 88. Grobholz R, Verbeke CS, Schleger C, Köhrmann KU, Hein B, Wolf G, Bleyl U, Spagnoli GC, Coplan K, Kolb D, Iversen K, Jungbluth AA. Expression of MAGE antigens and analysis of the inflammatory T-cell infiltrate in human seminoma. *Urol Res*, 2000, 28: 398-403
 89. Schafer D, Rosso R, Fricker R, Spagnoli G, Jundt G, Gerber H, Heberer M. Functional outcome of transplanted knee joints in dog. *Arch Ortop Trauma Surg*, 2000, 120: 426- 431.
 90. Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis K, Cerottini J-C, Lejeune F, Romero P, Valmori D. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and non primary open reading frame derived CTL epitopes in melanoma. *J Immunol*, 2000, 165: 7253-7261.
 91. Remmel E, Terracciano L, Noppen C, Zajac P, Heberer M, Spagnoli GC, Padovan E. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. *Hum Immunol*, 2001, 62: 39-49.
 92. Martin I, Jakob M, Schäfer D, Dick W, Spagnoli GC, Heberer M. Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic cartilage. *Osteoarthritis Cartilage*, 2001, 9:112-118 .
 93. Kavalari R, Sarcevic B, Spagnoli GC, Separovic V, Samija M, Terracciano L, Heberer M, Juretic A. Expression of MAGE tumor associated antigens is inversely correlated with tumor differentiation in invasive ductal breast cancers : an immunohistochemical study. *Virchows Arch*, 2001, 439: 127-131.

94. Certa U, Seiler M, Padovan E, Spagnoli GC. High density oligonucleotide array analysis of interferon- α 2a sensitivity and transcriptional response in melanoma cells. *Brit J Cancer*, 2001, 85: 107-114.
95. You Z, Hester J, Rollins L, Spagnoli GC, van der Bruggen P, Chen SY. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. *Cancer Res*, 2001, 61: 197-205.
96. Gross T, Martinoli S, Spagnoli G, Badia F, Malacrida R. Attitudes and behaviour of young european adults towards the donation of organs - a call for better information. *Am J Transpl*, 2001, 1: 74-81.
97. Schütz A, Oertli D, Marti W, Noppen C, Padovan E, Spagnoli G, Heberer M, Zajac P. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. *Cancer Gene Ther*, 2001, 8: 655-661.
98. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S. IL-1 β release in response to ryanodine receptor stimulation is increased in B-lymphocytes from patients susceptible to malignant hyperthermia. *J Biol Chem* 2001, 276: 48077-48082.
99. Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Spagnoli GC, Ladanyi M, Old LJ, Jungbluth AA. MAGE antigen expression in monophasic and biphasic synovial sarcoma. *Hum Pathol*, 2002, 35: 225-229.
100. Aubry F, Satie A-P, Rioux-Leclercq N, Rajpert-De Meyts E, Spagnoli GC, Chomez P, De Backer O, Jégou B, Samson M. MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. *Cancer*, 2001, 92: 2778-2785 .
101. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN- α 2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte derived dendritic cells and enhances their capacity to attract and stimulate CD8⁺ effector cells. *J Leuk Biol*, 2002, 71: 669-676.
102. Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC. Rapid induction of cytotoxic T-lymphocytes against melanoma associated antigens by a recombinant vaccinia virus vector expressing immunodominant epitopes and costimulatory molecules „in vivo“. *Hum Gene Ther*, 2002, 13: 569-575.
103. A-P Satie, Rajpert-De Meyts E, Spagnoli GC, Henno S, Olivo L, Krag Jacobsen G, Rioux-Leclercq N, Jégou B, Samson M. The cancer-testis gene NY-ESO-1 is expressed in

- normal foetal and adult testes and in spermatocytic seminomas and testicular CIS tumours. Lab Invest, 2002, 82: 775-780.*
104. *Jantscheff P, Spagnoli GC, Zajac P, Rochlitz C. Cell fusion : an approach to generate constitutively proliferating tumor antigen presenting cells. Cancer Immunol Immunother, 2002, in press.*
 105. *Padovan E, Terracciano L, Certa U, Jacobs B, Reschner A, Bolli M, Spagnoli GC, Borden EC, Heberer M. ISG15 constitutively produced by melanoma cells induces E-cadherin expression on human dendritic cells. Cancer Res, 2002, 62: 3453-3458.*
 106. *Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Rimmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser T, Heberer M, Sauter G, Spagnoli GC. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinomas of the urinary bladder: a tissue microarray study. Int J Cancer, 2002, 100: 702-705.*
 107. *Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC. Tissue microarray evaluation of MAGE tumor associated antigens expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg, 2002, 236:785-793.*
 108. *Resnick, MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E. Cancer-Testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer, 2002, 100: 190-195.*
 109. *Güller U, Zajac P, Schnider A, Bösch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real time quantitative PCR represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg, 2002, 236:768-775.*
 110. *Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, Oresic T, Juretic A. Expression of cancer/testis tumor associated antigens in squamous cell cervical carcinoma. Oncology, 2003, 64:443-449.*
 111. *Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour associated antigens: immunohistochemical detection with monoclonal antibodies. The Lancet Oncology, 2003, 4:104-109.*

112. Albo F, Cavazza A, Giardina B, Lippa S, Marini M, Roda LG, Spagnoli G. Degradation of the immunogenic peptide gp100 280-288 by the monocyte-like U937 cell line. *Peptides*, 2003, 24: 371-378.
113. Yakirevich E, Sabo E, Dirnfeld M, Sova Y, Spagnoli GC, Resnick MB. Morphometrical quantification of spermatogonial germ cells with the anti-MAGE-A4 antibody in the evaluation of testicular biopsies for azoospermia. *Appl Immunohistochem Mol Morphol*. 2003, 11:37-44.
114. Reschner A, Moretta A, Landmann R, Heberer M, Spagnoli GC, Padovan E. The ester-bonded palmitoyl side chains of Pam3CysSerLys4 lipopeptide account for its powerful adjuvanticity to HLA class I-restricted T lymphocytes. *Eur J Immunol* 2003, 33: 2044-2052
115. Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Gueller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G. Phase I/II clinical trial of a non replicative vaccinia virus expressing multiple HLA-A0201 restricted tumor associated epitopes and costimulatory molecules in metastatic melanoma patients. *Hum Gene Ther* 2003, 14:1497-1510.
116. Batchu RB, Moreno AM, Szmania S, Gupta SK, Zhan F, Rosen N, Kozlowski M, Spencer T, Spagnoli GC, Shaughnessy J, Barlogie B, Tricot G, van Rhee F. High-Level Expression of Cancer/Testis Antigen NY-ESO-1 and Human Granulocyte-Macrophage Colony-Stimulating Factor in Dendritic Cells with a Bicistronic Retroviral Vector. *Hum Gene Ther* 2003, 14:1333-1345.
117. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. *Clin Cancer Res*, 2003, 9:6453-6460.
118. Adamina M, Bolli M, Albo F, Cavazza A, Zajac P, Padovan E, Schumacher R, Reschner A, Feder C, Marti WR, Oertli D, Heberer M, Spagnoli GC. Encapsulation into sterically stabilized liposomes enhances the immunogenicity of melanoma associated Melan-A/MART-1 epitopes. *Br J Cancer*, 2004, 90:263-269.
119. Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli GC, Ferrari C, Missale G. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8⁺ cells in patients with hepatocellular carcinoma. *J Hepatol*, 2004, 40:102-109.
120. Albo F, Cavazza A, Giardina B, Marini M, Roda LG, Schumacher R, Spagnoli G. Degradation of the tumor antigen epitope gp100 280-288 by fibroblast-associated

- enzymes abolishes specific immunorecognition. *Biochim Biophys Acta*, 2004, 1761: 59-69.
121. Schumacher R, Adamina M, Zurbriggen R, Bolli M, Padovan E, Zajac P, Heberer M, Spagnoli GC. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. *Vaccine* 2004, 22: 714-723.
122. Cavazza A, Adamina M, Ausiello CM, Giardina B, Marini M, Palazzo R, Roda LG, Spagnoli G. Hydrolysis of the tumor-associated antigen epitope gp100280-288 by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. *Clin Immunol* 2004, 111:252-261.
123. Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K, Soslow RA. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. *Mod Pathol* 2005, 18:119-126.
124. Von Holzen U, Adamina M, Bolli M, Weber W, Zajac P, Groeper C, Reschner A, Feder C, Schumacher R, Marti W, Oertli D, Heberer M, Spagnoli GC. Selective responsiveness to common gamma chain cytokines in peripheral blood derived cytotoxic T lymphocytes induced by Melan-A/MART-1 27-35 targeted active specific immunotherapy. *Int J Cancer*, 2005, 115:248-255.
125. Feder-Mingus C, Schultz-Thater E, Oertli D, Marti W, Heberer M, Spagnoli GC, Zajac P. Non-replicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. *Hum Gene Ther*, 2005, 16:348-360.
126. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M, Reschner A. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. *J Cell Physiol*, 2005; 204:522-531.
127. Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, Carafa V, Terracciano L, Hudolin T, Spagnoli GC, Tornillo L. NY-ESO-1/LAGE-1 co-expression with MAGE-A cancer/testis antigens: a tissue microarray study. *Int J Cancer*, 2005, 115:960-966.
128. Spagnoli GC, Adamina M, Bolli M, Weber WP, Zajac P, Marti W, Oertli D, Heberer M, Harder F. Active antigen specific immunotherapy of melanoma: from basic science to clinical investigation. *World J Surg*, 2005, 29:692-699.
129. Van Rhee F, Szmania S, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor prognosis

- multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 2005, 105:3939-3944.*
130. Ghosh S, Rosenthal R, Zajac P, Weber WP, Oertli D, Heberer M, Martin I, Spagnoli GC, Reschner A. Culture of melanoma cells in three-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor associated antigen. *Ann Surg, 2005; 242:851-857.*
 131. Schumacher R, Amacker M, Neuhaus D, Rosenthal R, Groeper C, Heberer M, Spagnoli GC, Zurbriggen R, Adamina M. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L₂₇Melan-A/MART-1₂₆₋₃₅ peptide encapsulated into virosomes in vitro. *Vaccine, 2005, 23:5572-5582.*
 132. Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot GT, van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. *Cancer Res, 2005, 65:10041-10049.*
 133. T. Hudolin, A. Juretic, GC. Spagnoli, M. Heberer, M. Kosicek, M. Cacic and J. Pasini. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO-1 in cancerous and benign prostatic tissue. *Prostate, 2006; 66:13-18.*
 134. Weber WP, Feder-Mengus C, Chiarugi A, Rosenthal R, Reschner A, Schumacher R, Zajac P, Misteli H, Frey D, Oertli D, Heberer M, Spagnoli GC. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8⁺ T cells induced by TCR triggering or homeostatic cytokines. *Eur J Immunol, 2006; 3:296-304.*
 135. Trefzer U, Hofmann M, Reinke S, Guo YJ, Audring H, Spagnoli G, Sterry W. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. *Melanoma Res, 2006; 16:137-145.*
 136. Hudolin T, Juretic A, Pasini J, Tomas D, Spagnoli GC, Heberer M, Dimanovski J, Kruslin B. Immunohistochemical expression of tumour antigens MAGE-A1, MAGE-A3/4 and NY-ESO-1 in squamous cell carcinoma of the penis. *Urology, 2006; 68:205-207.*
 137. Cavazza A, Marini M, Spagnoli GC, Adamina M, Roda LG. Permeability of phospholipid vesicles to the tumor antigen gp100 280-288. *ChemMedChem, 2006, 1:816-820.*
 138. Adamina M, Schumacher R, Zajac P, Weber WP, Rosenthal R, Groeper C, Feder C, Zurbriggen R, Amacker M, Spagnoli GC, Oertli D, Heberer M. Advanced liposomal

- vectors as cancer vaccines in melanoma immunotherapy. *J Liposome Res*, 2006, 16:195-204.
139. Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A. Bone marrow mesenchymal stromal cells (BM-MSC) from healthy donors and autoimmune disease patients reduce the proliferation of autologous and allogenic stimulated lymphocytes in vitro. *Rheumatology*, 2007, 46:403-408.
 140. Haier J, Owzcareck M, Guller U, Spagnoli GC, Burger H, Senninger N, Kocher T. Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. *Anticancer Res*, 2006, 26:2281-2287.
 141. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. *Int J Cancer*, 2007, 120:337-343.
 142. Provenzano M, Panelli MC, Mocellin S, Bracci L, Sais G, Stroncek DF, Spagnoli GC, Marincola FM. MHC-peptide specificity and T cell epitope mapping: where immunotherapy starts. *Trends Mol Med*, 2006, 12:465-472.
 143. Peduzzi E, Groeper C, Schütte D, Zajac P, Rondini S, Mensah-Quainoo E, Spagnoli GC, Pluschke G, Daubenberger CA. Local activation of the innate immune system in Buruli ulcer lesions. *J Invest Dermatol*, 2007, 127:638-645.
 144. Adamina M, Guller U, Bracci L, Heberer M, Spagnoli G, Schumacher R. Clinical applications of virosomes in cancer immunotherapy. *Exp Opin Biol Ther*, 2006, &:1113-1121.
 145. Provenzano M, Bracci L, Wyler S, Hudolin T, Sais G, Gosert R, Zajac P, Palu G, Heberer M, Hirsch HH, Spagnoli GC. Characterization of highly frequent epitope-specific CD45RA⁺/CCR7^{+/-} lymphocyte responses against p53-binding domains of the human polyomavirus BK large T antigen in HLA-A*0201⁺ BKV-seropositive donors. *J Transl Med*, 2006, 4:47.
 146. Cavazza A, Marini M, Spagnoli GC, Roda LG. Effects of IL-1 on the hydrolysis of the tumor antigen epitope gp100 280-288 by fibroblast expressed enzymes. *Cytokines*, 2006, 36:189-198.
 147. Nelson PT, Zhang PJ, Spagnoli GC, Tomaszewski JE, Pasha TL, Frosina D, Caballero OL, Simpson AJG, Old LJ, Jungbluth AA. Cancer/testis (CT) antigens are expressed in fetal ovary. *Cancer Imm*, 2007, 7:1-7.

148. Feder-Mingus C, Ghosh S, Weber WP, Wyler S, Zajac P, Terracciano L, Oertli D, Heberer M, Martin I, Spagnoli GC, Reschner A. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen specific cytotoxic T lymphocytes. *Br J Cancer*, 2007, 96:1072-1082.
149. Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, Rughetti A, Muzii L, Nuti M, Benedetti Panici P. MAGE-A and NY-ESO-1 expression in cervical cancer: investigation on prognostic factors and effect of chemotherapy. *American Journal of Obstetrics and Gynecology*, 2008, 198:1-7.
150. Bracci L, Vukcevic M, Spagnoli G, Ducreux S, Zorzato F, Treves S. Ca^{2+} signaling through ryanodine receptor 1 enhances maturation and activation of human dendritic cells. *J Cell Sci*, 2007, 120: 2232-2240.
151. Ghosh S, Joshi MB, Ivanov D, Feder-Mingus C, Spagnoli GC, Martin I, Erne P, Resink TJ. Use of multicellular tumor spheroids to dissect endothelial cell-tumor cell interactions: a role for T-cadherin in tumor angiogenesis. *FEBS Lett*, 2007, 581:4523-4528.
152. Jungbluth AA, Silva WA, Iversen K, Frosina D, Zaidi B, Coplan K, Eastlake-Wade SK, Castelli SB, Spagnoli GC, Old LJ, Vogel M. Expression of cancer-testis antigens in placenta. *Cancer Imm*, 2007; 7:15-27
153. Adamina M, Weber WP, Rosenthal R, Schumacher R, Zajac P, Guller U, Frey DM, Oertli D, Zuber M, Heberer M, Spagnoli GC. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. *Contemp Clin Trials* 2007, 29:165-181.
154. Bellati F, Napoletano C, Tarquini E, Palaia I, Landi R, Mancini N, Spagnoli G, Rughetti A, Benedetti Panici L, Nuti M. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. *Eur J Cancer*, 2007, 43:2621-2617
155. Rosenthal R, Viehl CT, Güller U, Weber WP, Adamina M, Spagnoli GC, Heberer M, Zuber M. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. *J Am Coll Surgeons* 2008, 207:95-105.
156. Bracci L, Schumacher R, Provenzano M, Adamina M, Rosenthal R, Groeper C, Zajac P, Iezzi G, Proietti E, Belardelli F, Spagnoli GC. Efficient stimulation of T cell responses by human IFN- α induced dendritic cells does not require Toll-like receptor triggering. *J Immunother*, 2008, 31:466-474

157. Perez D, Herrmann T, Jungbluth AA, Samartzis P, Spagnoli G, Demartines N, Clavien PA, Marino S, Seifert B, Jager D. Cancer Testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. *Int J Cancer*, 2008, 123:1551-1555.
158. Feder-Mengus C, Wyler S, Hudolin T, Ruzsat R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A, Gasser TC, Sulser T, Heberer M, Spagnoli GC, Provenzano M. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. *Eur J Cancer*, 2008, 44:2266-2275.
159. Feder-Mengus C, Ghosh S, Reschner A, Martin I, Spagnoli GC. New dimensions in tumor immunology: what does 3D culture reveal? *Trends Mol Med*, 2008, 14:333-340.
160. Cavazza A, Marini M, Spagnoli GC, Roda LG. Positive and negative modulation of peptidases by pro-inflammatory cytokines. *Peptides*, 2008, 29:1974-1981.
161. Bocelli-Tyndall, Bracci L, Schaeren S, Feder-Mengus C, Barbero A, Tyndall A, Spagnoli G. Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated with the cytokines IL 2, IL 7 and IL 15. *Ann Rheum Dis*, 2008, 68:1352-1359.
162. Provenzano M, Sais G, Bracci L, Egli A, Anselmi M, Viehl CT, Schaub S, Hirsch HH, Stroncek DF, Marincola FM, Spagnoli GC. A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities. *J Cell Mol Med*, 2009, 13:2131-2147.
163. Rosenthal R, Groeper C, Bracci L, Adamina M, Feder-Mengus C, Zajac P, Iezzi G, Bolli M, Weber W, Frey D, Von Holzen U, Oertli D, Heberer M, Spagnoli G. Differential responsiveness to IL-2, -7 and -15 common receptor γ chain cytokines by antigen specific peripheral blood naïve or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. *J Immunother* 2009, 32:252-261.
164. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L. Defective infiltration of NK cells in MIC-A/B positive renal cell carcinoma involves β 2 integrin mediated interaction. *Neoplasia*, 2009, 11:662-671.
165. Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G, Iezzi G, Spagnoli G, Bihl M, Terracciano L, Zlobec I. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a "pro-/anti-tumour" approach to tumour host interaction in colorectal cancer. *Br J Cancer*, 2009, 101:1382-1392.

166. Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, Huegli RW, Jacob AL, Heberer M, Oertli D, Marti W, Spagnoli GC, Zajac P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and co-stimulatory molecules in metastatic melanoma. *Mol Ther*, 2010, 18:651-659.
167. Schatton T, Schütte U, Frank NY, Zhan Q, Hörning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Modulation of T cell activation by malignant melanoma initiating cells. *Cancer Res*, 2010, 70:697-708.
168. Pastorcic Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli GC, Grgic M. Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. *Head and Neck*, 2010, 32:1178-1184.
169. Spagnoli GC, Ebrahimi M, Iezzi G, Mengus C, Zajac P. Contemporary immunotherapy of solid tumors: from tumor associated antigens to combination treatments. *Curr Opin Drug Disc Dev*, 2010, 13:184-192.
170. Vukcevic M, Zorzato F, Spagnoli G, Treves S. Frequent calcium oscillations lead to NFAT activation in human immature dendritic cells. *J Biol Chem*, 2010, 285:16003-16011.
171. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM and ALDH1 in colorectal cancer. *Br J Cancer*, 2010, 103: 382-390.
172. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC. Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. *Int J Cancer*, 2011, 128:2663-2672.
173. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N, Goldhirsch A. Cancer-testis antigen expression in triple-negative breast cancer. *Ann Oncol*, 2011, 22:98-103.
174. Bocelli-Tyndall C, Zajac P, Di Maggio N, Trella E, Scherberich A, Iezzi G, Benvenuto F, Barbero A, Schaeren S, Pistoia V, Spagnoli GC, Vukcevic M, Martin I, Tyndall A. FGF-2 and PDGF but not platelet lysate (PL) induce proliferation dependent functional MHC-class II antigens in human mesenchymal stem cells (MSC), *Arthritis Rheum*, 2010, 62: 3815-3825.

175. Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, Terracciano L, Tornillo L, Spagnoli GC. *MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin, and urothelial malignancies. Int J Cancer* 2011, 129:1137-1148.
176. Figueredo DL, Mamede RC, Spagnoli GC, Silva WAJr, Zago M, Neder L, Jungbluth AA, Saggiaro FP. *High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck*, 2011, 33:702-707.
177. Zlobec I, Karamitopoulou E, Terracciano L, Piscuoglio S, Iezzi G, Muraro MG, Spagnoli G, Baker K, Tzankov A, Lugli A. *TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. Plos One*, 2010, 5(12):e 14282.
178. Pfaff D, Philippova M, Kyriakakis E, Maslova K, Rupp K, Buechner SA, Iezzi G, Spagnoli GC, Erne P, Resink TJ. *Paradoxical effects of T-cadherin on squamous cell carcinoma: up- and downregulation increase xenograft growth by distinct mechanisms. J Pathol*, 2011, 225:512-524.
179. Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S, Jungbluth AA. *Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother* 2011, 60:999-1007.
180. Mengus C, Le Magnen C, Trella E, Kawa J, Bubendorf L, Provenzano M, Bachmann A, Heberer M, Spagnoli GC, Wyler S. *Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer" J Transl Med*, 2011, 9:162.
181. Montoro JR, Mamede RC, Neder Serafini L, Saggiaro FP, Figueredo DL, Silva WA Jr, Jungbluth AA, Spagnoli GC, Zago MA. *Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head and Neck*, 2011, 34: 1123-1128.
182. Raafat N, Sadowski-Cron C, Mengus C, Heberer M, Spagnoli GC, Zajac P. *Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. Int J Cancer*, 2012, 131:E659-669.


183. Badovinac Crnjevic T, Juretic A, Jakic-Razumovic J, Spagnoli GC, Saric N, Podolski P. High expression of MAGE-A10 cancer/testis antigen in triple negative breast cancers. *Med Oncol*, 2012, 29: 1586-91.
184. Droeser R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, Oertli D, Tapia C. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. *BMC Cancer*, 2012, 12:134.
185. Möller I, Spagnoli GC, Veelken H, Houet L. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naive T-cell subtypes. *Cancer Immunol Immunother*, 2012, 61:2079-90.
186. Sais G, Wyler S, Hudolin T, Banzola I, Mengus C, Bubendorf L, Wild PJ, Hirsch HH, Sulser T, Spagnoli GC, Provenzano M. Differential patterns of large tumor antigen specific immune responsiveness in patients with BKV polyomavirus positive prostate cancer or benign prostatic hyperplasia. *J Virol* 2012, 86:8461-71.
187. Muraro M, Mele V, Däster S, Han J, Heberer M, Spagnoli GC, Iezzi G. CD133+, CD166+/CD44+ or CD24+/CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cell lines. *Stem Cells Translational Medicine*, 2012, 1:592-603.
188. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. *Letter. Cancer Res* 2012, 72:5428-29.
189. Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann M, Spagnoli GC, Wyler S, Mengus C. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. *Eur J Cancer*, 2012, 49:955-63.
190. Mengus C, Schultz-Tater E, Coulot J, Kastelan Z, Goluzza E, Coric M, Spagnoli G, Hudolin T. MAGE-A10 cancer/testis antigen is highly expressed in high grade non muscle invasive bladder carcinomas. *Int J Cancer*, 2013, 132:2459-63.
191. Philippova M, Pfaff D, Kyriakakis E, Buechner S, Iezzi G, Spagnoli GC, Erne P, Resink TJ. T-Cadherin loss in squamous cell carcinoma promotes experimental metastasis in vivo and extravasation in vitro. *Eur J Cancer*, 2013, 49:2048-58.
192. Droeser R, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Heberer M, Iezzi G, Amicarella F, Cremonesi E, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli G, Tornillo L.

- Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer, 2013, 49: 2233-42.*
193. Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker C, Rosso R, Zuber M, Amicarella F, Iezzi G, Sconocchia G, Heberer M, Lugli A, Tornillo L, Oertli D, Terracciano L, Spagnoli GC. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. *PLoSOne, 2013, e64814.*
 194. Hudolin T, Kastelan Z, Ilic I, Levarda-Hudolin K, Basic-Jukic N, Rieken M, Spagnoli GC, Juretic A, Mengus C. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. *J Transl Med 2013, 11:123.*
 195. Bhattacharjee M, Schultz-Thater E, Trella E, Das S, Miot S, Loparic M, Ray AR, Martin I, Spagnoli GC, Ghosh S. The role of 3D structure and protein conformation on the innate and adaptive immune responses to silk-based biomaterials. *Biomaterials, 2013, 34:8161-71.*
 196. Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini M, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC. Characterization and clinical relevance of ALDH^{bright} populations in prostate cancer. *Clin Cancer Res, 2013, 19: 5361-71.*
 197. Hirt C, Eppenberger-Castori S, Sconocchia G, Iezzi G, Tornillo L, Terracciano L, Spagnoli GC, Droeser RA. Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. *Oncoimmunology. 2013, 2: e25990.*
 198. Mele V, Muraro MG, Calabrese D, Pfaff D, Amatruda N, Amicarella F, Kvinlaug B, Bocelli-Tyndall C, Martin I, Resink TJ, Heberer M, Oertli D, Terracciano LM, Spagnoli GC, Iezzi G. Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF- β . *Int J Cancer, 2014, 134: 2583-94.*
 199. Bocelli-Tyndall C, Trella E, Frachet A, Zajac P, Pfaff D, Geurts J, Heiler S, Barbero A, Mumme M, Resink T, Schaeren S, Spagnoli GC, Tyndall A. FGF2 induces RANKL gene expression as well as IL1 β regulated MHC class II in bone marrow derived human mesenchymal progenitor stromal cells. *Ann Rheum Dis, 2015, 74:260-6.*
 200. Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoupou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L. HLA

- class II antigen expression in colorectal cancer as a favourable prognostic marker. Neoplasia, 2014, 16: 31-42.*
201. Laban S, Atanackovic D, Lützens T, Knecht R, Busch C-J, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Münscher A, Clauditz TS. Simultaneous cytoplasmic and nuclear protein expression of MAGE-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head & neck cancer. *Int J Cancer* 2014, 135:1142-1152.
 202. Nebiker C, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F, Cremonesi E, Huber X, Padovan E, Angrisani B, Droeser RA, Rosso R, Bolli M, Oertli D, von Holzen U, Adamina M, Muraro MG, Mengus C, Zajac P, Sconocchia G, Zuber M, Tornillo L, Terracciano L, Spagnoli GC. GM-CSF production by tumor cells is associated with improved survival in colorectal cancer. *Clin Cancer Res* 2014, 20:3094-3106.
 203. Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz V, Schlaak M, Kvasnicka H-M, Spagnoli G, Dirnhöfer S, Speiser DE, Von Bergwelt-Baildon M, Zippelius A. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. *Cancer Immunol Res* 2014, 2:741-755.
 204. Hirt C, Papadimitropoulos A, Mele V, Muraro MG, Mengus C, Iezzi G, Terracciano L, Martin I, Spagnoli GC. "In vitro" 3D models of tumor-immune system interaction. *Advanced Drug Delivery Reviews*, 2014, 79-80: 145-54.
 205. Däster S, Eppenberger-Castori S, Hirt C, Zlobec I, Delko T, Nebiker CA, Soysal SD, Amicarella F, Iezzi G, Sconocchia G, Heberer M, Lugli A, Spagnoli GC, Kettelhack C, Terracciano L, Oertli D, von Holzen U, Tornillo L, Droeser RA. High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. *Dis Markers* 2014: 792183
 206. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Iezzi G, Terracciano L, Ferrone S. NK cell-T cell cooperation and clinical course of colorectal cancer. *Oncoimmunology*, 2014, 3(8)e952197..
 207. Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjjatic S, Spagnoli G, Lele S, Odunsi K. Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. *PLoS One*. 2014 , 9: e104099

208. Sesia S, Duhr R, Medeiros da Cunha C, Todorov A, Schaeren S, Padovan E, Spagnoli G, Martin I, Barbero A. *Anti-inflammatory/tissue repair macrophages enhance the cartilage-forming capacity of human bone marrow-derived mesenchymal stromal cells.* *J Cell Physiol*, 2015, 230:1258-69.
209. Weixler B, Cremonesi E, Sorge R, Muraro MG, Delko T, Däster S, Governa V, Amicarella F, Soysal SD, Kettelhack C, von Holzen UW, Eppenberger-Castori S, Spagnoli GC, Oertli D, Iezzi G, Terracciano L, Tornillo L, Sconocchia G, Droeser RA. *OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.* *Oncotarget* 2015, 6:37588-99.
210. Däster S, Eppenberger-Castori S, Hirt C, Delko T, Nebiker CA, Weixler B, Amicarella F, Iezzi G, Governa V, Padovan E, Mele V, Sconocchia G, Heberer M, Terracciano L, Kettelhack C, Oertli D, Spagnoli GC, von Holzen U, Tornillo L, Droeser RA. *Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis.* *Oncoimmunology*, 2015, 4(12) e1050574.
211. Hirt C, Papadimitriopoulos A, Muraro MG, Mele V, Panopoulos E, Cremonesi E, Ivanek R, Schultz-Thater E, Droeser RA, Mengus C, Heberer M, Oertli D, Iezzi G, Zajac P, Eppenberger-Castori S, Tornillo L, Terracciano L, Martin I, Spagnoli GC. *Bioreactor-engineered cancer tissue-like structures mimic phenotypes, gene expression profiles and drug resistance patterns observed "in vivo".* *Biomaterials*, 2015, 62:138-146.
212. Arriga R, Caratelli S, Coppola A, Spagnoli G, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe M, Maurillo L, Buccisano F, Capuani B, Ferrone S. *Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage.* *Oncotarget*, 2016, 12:2070-79.
213. Trella E, Raafat N, Mengus C, Traunecker S, Governa V, Heidtmann S, Heberer M, Oertli D, Spagnoli GC, Zajac P. *CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8⁺ central memory T cells.* *Eur J Immunol*, 2016, 46:420-31
214. Antonelli G, Spagnoli G. *Why do infections cause cancer?* *Clin Microbiol Infect*, 2015, 21:967-8.

Total number of citations: 6665. H Index: 44 (Web of Science).

A handwritten signature in black ink, reading "Michio C. Soguel". The signature is written in a cursive style with a long, sweeping underline that extends to the left.